Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Melanoma Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Chemotherapy
  • 1.3.3 Immunotherapy
  • 1.3.4 Targeted Therapy
• 1.4 Market Segment by Application
  • 1.4.1 Global Melanoma Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Clinics
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Melanoma Drugs Market Size
  • 2.1.1 Global Melanoma Drugs Revenue 2014-2025
  • 2.1.2 Global Melanoma Drugs Sales 2014-2025
• 2.2 Melanoma Drugs Growth Rate by Regions
  • 2.2.1 Global Melanoma Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Melanoma Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Melanoma Drugs Sales by Manufacturers
  • 3.1.1 Melanoma Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Melanoma Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Melanoma Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Melanoma Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Melanoma Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Melanoma Drugs Price by Manufacturers
• 3.4 Key Manufacturers Melanoma Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Melanoma Drugs Market
• 3.6 Key Manufacturers Melanoma Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Chemotherapy Sales and Revenue (2014-2019)
  • 4.1.2 Immunotherapy Sales and Revenue (2014-2019)
  • 4.1.3 Targeted Therapy Sales and Revenue (2014-2019)
• 4.2 Global Melanoma Drugs Sales Market Share by Type
• 4.3 Global Melanoma Drugs Revenue Market Share by Type
• 4.4 Melanoma Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Melanoma Drugs Sales by Application

6 United States

• 6.1 United States Melanoma Drugs Breakdown Data by Company
• 6.2 United States Melanoma Drugs Breakdown Data by Type
• 6.3 United States Melanoma Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Melanoma Drugs Breakdown Data by Company
• 7.2 European Union Melanoma Drugs Breakdown Data by Type
• 7.3 European Union Melanoma Drugs Breakdown Data by Application

8 China

• 8.1 China Melanoma Drugs Breakdown Data by Company
• 8.2 China Melanoma Drugs Breakdown Data by Type
• 8.3 China Melanoma Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Melanoma Drugs Breakdown Data by Company
• 9.2 Rest of World Melanoma Drugs Breakdown Data by Type
• 9.3 Rest of World Melanoma Drugs Breakdown Data by Application
• 9.4 Rest of World Melanoma Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Melanoma Drugs Sales by Countries
  • 9.4.2 Rest of World Melanoma Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Amgen
  • 10.1.1 Amgen Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.1.4 Melanoma Drugs Product Introduction
  • 10.1.5 Amgen Recent Development
• 10.2 Bristol-Myers Squibb
  • 10.2.1 Bristol-Myers Squibb Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.2.4 Melanoma Drugs Product Introduction
  • 10.2.5 Bristol-Myers Squibb Recent Development
• 10.3 Roche
  • 10.3.1 Roche Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.3.4 Melanoma Drugs Product Introduction
  • 10.3.5 Roche Recent Development
• 10.4 Genentech
  • 10.4.1 Genentech Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.4.4 Melanoma Drugs Product Introduction
  • 10.4.5 Genentech Recent Development
• 10.5 Janssen Biotech
  • 10.5.1 Janssen Biotech Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.5.4 Melanoma Drugs Product Introduction
  • 10.5.5 Janssen Biotech Recent Development
• 10.6 Novartis
  • 10.6.1 Novartis Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.6.4 Melanoma Drugs Product Introduction
  • 10.6.5 Novartis Recent Development
• 10.7 Pfizer
  • 10.7.1 Pfizer Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.7.4 Melanoma Drugs Product Introduction
  • 10.7.5 Pfizer Recent Development
• 10.8 Sanofi
  • 10.8.1 Sanofi Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.8.4 Melanoma Drugs Product Introduction
  • 10.8.5 Sanofi Recent Development
• 10.9 Takeda Pharma
  • 10.9.1 Takeda Pharma Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.9.4 Melanoma Drugs Product Introduction
  • 10.9.5 Takeda Pharma Recent Development
• 10.10 Teva Pharma
  • 10.10.1 Teva Pharma Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Melanoma Drugs
  • 10.10.4 Melanoma Drugs Product Introduction
  • 10.10.5 Teva Pharma Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Melanoma Drugs Sales Channels
  • 11.2.2 Melanoma Drugs Distributors
• 11.3 Melanoma Drugs Customers

12 Market Forecast

• 12.1 Global Melanoma Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Melanoma Drugs Sales Forecast by Type
• 12.3 Global Melanoma Drugs Sales Forecast by Application
• 12.4 Melanoma Drugs Forecast by Regions
  • 12.4.1 Global Melanoma Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Melanoma Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the skin and is most common because most pigment cells are found in the skin. Mucosal melanoma is melanoma of mucous membrane of the body, including the mouth, the nasal passages, the throat, the vagina or the anus. The rare ocular melanoma or uveal melanoma occurs in the eye.
In 2019, the market size of Melanoma Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Melanoma Drugs.

This report studies the global market size of Melanoma Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Melanoma Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Amgen
Bristol-Myers Squibb
Roche
Genentech
Janssen Biotech
Novartis
Pfizer
Sanofi
Takeda Pharma
Teva Pharma

Market Segment by Product Type
Chemotherapy
Immunotherapy
Targeted Therapy

Market Segment by Application
Hospitals
Clinics
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Melanoma Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Melanoma Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Melanoma Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025